Management of experimental trabeculectomy filtering blebs via crosslinking of the scleral flap inhibited vascularization.

Graefes Arch Clin Exp Ophthalmol

Department of Ophthalmology, the First Affiliated Hospital of Soochow University, Shizi Street 188, Suzhou, 21006, Jiangsu Province, China.

Published: May 2024

Purpose: The aim of this study was to evaluate whether UVA-light-activated riboflavin-induced collagen crosslinking (UVA-CXL) can maintain the function of filtering blebs after trabeculectomy (TRAB) in rabbits.

Methods: Thirty-six healthy rabbits were randomized to one of the following groups with 12 rabbits in each group: Trabeculectomy group (TRAB group), trabeculectomy combined with CXL group (CXL group), and trabeculectomy combined with MMC group (MMC group). Six rabbits of each group were performed with intraocular pressure (IOP), optical coherence tomography (OCT), and OCT angiography (OCTA). Bleb structure was observed via hematoxylin & eosin (H&E) and Masson staining. Immunohistochemistry, proteomic study, western blot, and tensile test were performed between CXL group and the control. In vitro, cell viability was evaluated by CCK-8 and Calcein/PI staining. TRPV4 and VEGF-a expression levels were measured by Q-PCR. Ca concentration was observed with Fluo-4 AM.

Results: The IOP and bleb median survival day were significantly modified in CXL (5.92 ± 0.32 mmHg and 15.5 days) than TRAB group (7.50 ± 0.43 mmHg and 9 days). The bleb area and height increased. CXL inhibited vascularization, and vascularization peaked at postoperative day (POD) 14 and then decreased gradually. In proteomic analyses, Z disc, actin filament binding, and sarcomere organization were significantly enriched. CXL inhibited scleral stress‒strain in tensile tests. Compared with TRAB group, TRPV4 expression was significantly increased, but VEGF-a and TGF-β1 levels were reduced in the CXL group in western blot. Meanwhile, TRPV4 expression colocalized with CD31. In vitro, CXL inhibited HUVECs cell viability. After CXL, expression level of TRPV4 was increased and calcium influx was activated, but VEGF-a was decreased in HUVECs.

Conclusions: This study demonstrates that intraoperative UV-RF CXL can significantly improve the success rate of TRAB via inhibiting filtering bleb vascularization. CXL increased sclera stiffness, in turn, induced TRPV4 activation, thus contributing to vascular endothelial cells suppression.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00417-023-06306-8DOI Listing

Publication Analysis

Top Keywords

cxl group
16
group
12
group trabeculectomy
12
trab group
12
cxl inhibited
12
cxl
11
filtering blebs
8
inhibited vascularization
8
rabbits group
8
trabeculectomy combined
8

Similar Publications

Aim: To report the clinical and therapeutic particularities of pediatric keratoconus (KC).

Methods: Retrospective study focusing on patients aged less than 18 years, presenting with KC and followed in a tertiary reference center in Sfax, Tunisia.

Results: Our study involved 38 eyes of 20 children.

View Article and Find Full Text PDF

Purpose: To investigate the effectiveness and safety of accelerated epithelium-on crosslinking to stabilize tomographically suspicious fellow eyes of young patients with unilateral clinically evident keratoconus (KC) compared with observation alone.

Methods: This retrospective observational study included 43 fellow eyes of 43 young patients with unilateral clinically evident KC who completed a 24-month follow-up. Twenty-four eyes underwent accelerated epithelium-on crosslinking [epi-on corneal crosslinking (CXL) group] and 19 eyes were observed (observation group).

View Article and Find Full Text PDF

Keratoconus is a burden to health systems and patients worldwide. Corneal collagen crosslinking (CXL) treatment has been shown abroad to be cost-effective for treating progressive keratoconus. However, no cost-effectiveness studies have been performed in Brazil.

View Article and Find Full Text PDF
Article Synopsis
  • Early neurological deterioration (END) is linked to poor outcomes in acute ischemic stroke (AIS), and the study investigates how the drug evolocumab can help prevent this condition by lowering LDL cholesterol levels.
  • The research was a clinical trial with AIS patients divided into two groups: one receiving evolocumab combined with atorvastatin and the other receiving atorvastatin alone, assessing outcomes like END rates and inflammatory markers over 7 days.
  • Results showed that the combination therapy group had significantly lower rates of END (13.2% vs. 24.3%) and a much higher LDL cholesterol target achievement rate (74.3% vs. 14.7%), indicating the effectiveness of evolocumab in this context.
View Article and Find Full Text PDF

The increasing utilization of cannabis products combined with lack of data regarding potential cannabis-prescription drug interactions is concerning. This study aimed to review published case reports and FDA Adverse Event Reporting System (FAERS) spontaneous reports to assess cannabis-drug interactions in persons aged 18 and over. A literature search identified 20 case reports that were each assessed for drug interaction causality using the Drug Interaction Probability Scale.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!